Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Molecular rationale for the use of PI3K/AKT/mTOR pathway inhibitors in combination with crizotinib in ALK-mutated neuroblastoma.

Oncotarget - 30 Sept 2014

Moore Nathan F, Azarova Anna M, Bhatnagar Namrata, Ross Kenneth N, Drake Lauren E, Frumm Stacey, Liu Qinsong S, Christie Amanda L, Sanda Takaomi, Chesler Louis, Kung Andrew L, Gray Nathanael S, Stegmaier Kimberly, George Rani E

Abstract excerpt

Mutations in the ALK tyrosine kinase receptor gene represent important therapeutic targets in neuroblastoma, yet their clinical translation has been challenging. The ALK(F1174L) mutation is sensitive to the ALK inhibitor crizotinib only at high doses and mediates acquired resistance to crizotinib in ALK-translocated cancers. We have shown that the combination of crizotinib and an inhibitor of downstream signaling...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anaplastic Lymphoma Kinase
Share to Crizotinib

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mechanistic Target of Rapamycin Complex 1

Share to N-Myc Proto-Oncogene Protein

Share to Oncogene Proteins

Share to Phosphatidylinositol 3-Kinase

Share to Phosphoinositide-3 Kinase Inhibitors

Share to Pyrazoles

Source

Open in PubMed Open full text

Identifiers

PMID: 25228590
DOI: 10.18632/oncotarget.2372
PMCID: PMC4226718

Genes

ALK
MYCN
RPS6

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Molecular rationale for the use of PI3K/AKT/mTOR pathway inhibitors in combination with crizotinib in ALK-mutated neuroblastoma.PMID 25228590Read ↗

The ALK(F1174L) mutation potentiates the oncogenic activity of MYCN in neuroblastoma.Semantic proximity Read ↗

The ALK inhibitor PF-06463922 is effective as a single agent in neuroblastoma driven by expression of ALK and MYCN.Semantic proximity Read ↗

The neuroblastoma-associated F1174L ALK mutation causes resistance to an ALK kinase inhibitor in ALK-translocated cancers.Semantic proximity Read ↗

The ALK/ROS1 Inhibitor PF-06463922 Overcomes Primary Resistance to Crizotinib in ALK-Driven Neuroblastoma.Semantic proximity Read ↗

Inhibition of ALK Signaling for Cancer TherapySemantic proximity Read ↗

Novel ALK inhibitor AZD3463 inhibits neuroblastoma growth by overcoming crizotinib resistance and inducing apoptosis.Semantic proximity Read ↗

Strategies for co-targeting the PI3K/AKT/mTOR pathway in NSCLC.Semantic proximity Read ↗

Dual ALK and CDK4/6 Inhibition Demonstrates Synergy against Neuroblastoma.Semantic proximity Read ↗

Targeting ALK: a promising strategy for the treatment of non-small cell lung cancer, non-Hodgkin's lymphoma, and neuroblastoma.Semantic proximity Read ↗

PI3King the LockSemantic proximity Read ↗

Crizotinib Synergizes with Chemotherapy in Preclinical Models of Neuroblastoma.Semantic proximity Read ↗

Differential inhibitor sensitivity of anaplastic lymphoma kinase variants found in neuroblastoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.